BRPI0607412A2 - preparação de ação retardada em forma de péletes contra vertigem - Google Patents

preparação de ação retardada em forma de péletes contra vertigem

Info

Publication number
BRPI0607412A2
BRPI0607412A2 BRPI0607412-0A BRPI0607412A BRPI0607412A2 BR PI0607412 A2 BRPI0607412 A2 BR PI0607412A2 BR PI0607412 A BRPI0607412 A BR PI0607412A BR PI0607412 A2 BRPI0607412 A2 BR PI0607412A2
Authority
BR
Brazil
Prior art keywords
preparation
pellets
delayed action
vertigo
pharmaceutical composition
Prior art date
Application number
BRPI0607412-0A
Other languages
English (en)
Inventor
Gernot Francas
Original Assignee
Hennig Arzneimittel Gmbh & Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hennig Arzneimittel Gmbh & Co filed Critical Hennig Arzneimittel Gmbh & Co
Publication of BRPI0607412A2 publication Critical patent/BRPI0607412A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Otolaryngology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Fireproofing Substances (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

PREPARAçãO DE AçãO RETARDADA EM FORMA DE PéLETES CONTRA VERTIGEM. A presente invenção refere-se a uma composição farmacêutica de uma preparação de ação retardada em forma de péletes, para o tratamento de vertigem seja qual for a gênese. Portanto, é descrita uma composição farmacêutica contendo cinarizina e dimenidrinato, sendo que a liberação de substâncias ativas é retardada e a preparação está presente em forma de péletes. A composição farmacêutica contém, adicionalmente, aglutinante, agente de retardamento e cargas.
BRPI0607412-0A 2005-03-23 2006-03-23 preparação de ação retardada em forma de péletes contra vertigem BRPI0607412A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102005014142A DE102005014142B4 (de) 2005-03-23 2005-03-23 Pelletförmige Retardzubereitung gegen Schwindel
PCT/DE2006/000546 WO2006099864A2 (de) 2005-03-23 2006-03-23 Pelletförmige retardzubereitung enthaltend cinnarizin und dimenhydrinat gegen schwindel

Publications (1)

Publication Number Publication Date
BRPI0607412A2 true BRPI0607412A2 (pt) 2009-09-01

Family

ID=36732469

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0607412-0A BRPI0607412A2 (pt) 2005-03-23 2006-03-23 preparação de ação retardada em forma de péletes contra vertigem

Country Status (14)

Country Link
US (1) US20090298852A1 (pt)
EP (1) EP1874314B1 (pt)
JP (1) JP2008534451A (pt)
KR (1) KR20080003324A (pt)
CN (1) CN101141963B (pt)
AT (1) ATE477801T1 (pt)
BR (1) BRPI0607412A2 (pt)
CA (1) CA2602209A1 (pt)
DE (2) DE102005014142B4 (pt)
DK (1) DK1874314T3 (pt)
ES (1) ES2349996T3 (pt)
PT (1) PT1874314E (pt)
RU (1) RU2401110C2 (pt)
WO (1) WO2006099864A2 (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10301981A1 (de) * 2003-01-15 2004-07-29 Hennig Arzneimittel Gmbh & Co. Kg Kombinationspräparat gegen Schwindel
DE102010062810B4 (de) * 2010-09-07 2014-03-13 Immungenetics Ag 2-(R2-Thio)-10-[3-(4-R1-piperazin-1-yl)propyl]-10H-phenothiazine zur Behandlung neurodegenerativer Erkrankungen ausgewählt aus beta-Amyloidopathien und alpha-Synucleinopathien
HUE047420T2 (hu) 2011-05-05 2020-04-28 Hennig Arzneimittel Gmbh&Co Kg Dózisforma a hatóanyag szabályozott kibocsájtására
DE102011075354A1 (de) 2011-05-05 2012-11-08 Hennig Arzneimittel Gmbh & Co. Kg Arzneiform zur gezielten Freigabe von Wirkstoffen
DE102011051308A1 (de) * 2011-06-24 2012-12-27 Hennig Arzneimittel Gmbh & Co. Kg Herstellungsverfahren und Arzneiform
AU2013369379B2 (en) * 2012-12-27 2018-03-15 Hennig Arzneimittel Gmbh & Co. Kg Monolithic dosage form for the modified release of an active ingredient combination
EP2959887B1 (de) * 2014-06-26 2018-11-14 Hennig Arzneimittel GmbH&Co. Kg Arzneimittel zur Behandlung von Schwindel verschiedener Genese
EP3607949B1 (en) 2018-04-25 2025-02-26 Oncocross Co., Ltd. Dimenhydrinate and calcium pantothenate for preventing and treating muscular disease

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4792452A (en) * 1987-07-28 1988-12-20 E. R. Squibb & Sons, Inc. Controlled release formulation
DE10301981A1 (de) * 2003-01-15 2004-07-29 Hennig Arzneimittel Gmbh & Co. Kg Kombinationspräparat gegen Schwindel

Also Published As

Publication number Publication date
EP1874314A2 (de) 2008-01-09
DE502006007693D1 (de) 2010-09-30
WO2006099864A2 (de) 2006-09-28
ES2349996T3 (es) 2011-01-14
DK1874314T3 (da) 2010-11-22
JP2008534451A (ja) 2008-08-28
DE102005014142A1 (de) 2006-10-05
RU2007137435A (ru) 2009-04-27
CA2602209A1 (en) 2006-09-28
HK1112404A1 (zh) 2008-09-05
PT1874314E (pt) 2010-11-15
EP1874314B1 (de) 2010-08-18
WO2006099864A3 (de) 2007-02-08
CN101141963B (zh) 2012-07-04
US20090298852A1 (en) 2009-12-03
DE102005014142B4 (de) 2006-11-09
CN101141963A (zh) 2008-03-12
RU2401110C2 (ru) 2010-10-10
ATE477801T1 (de) 2010-09-15
KR20080003324A (ko) 2008-01-07

Similar Documents

Publication Publication Date Title
IL196108A0 (en) Active agent formulations, methods of making, and methods of use
WO2006124047A3 (en) Pharmaceutical formulations containing microparticles or nanoparticles of a delivery agent
WO2006096439A3 (en) Pharmaceutical compositions for the treatment and/or prevention of schizophrenia and related diseases
WO2007087068A3 (en) Inhibitors of tyrosine kinases and uses thereof
IL192763A (en) History of pyrimidine, preparations containing them and used in the preparation of cancer drugs
ZA200705750B (en) Compositions and methods for stabilizing active pharmaceutical ingredients
WO2009007328A3 (de) Verwendung von homo- und copolymeren zur stabilisierung von wirkstoffformulierungen
IL183357A0 (en) Oral medicament for the modified release of at least one active principle, in multimicrocapsule form
MX2009007254A (es) Composiciones de tableta en tableta.
TW200730202A (en) Solid dosage form
PL1890681T3 (pl) Kompozycja granulowana na sucho zawierająca emtrycytabinę i tenofowir DF
IL219216A0 (en) A pharmaceutical composition for treating cancer comprising trypsinogen and/or chymotrypsinogen and an active agent selected from a selenium compound, a vanilloid compound and a cytoplasmic glycolysis reduction agent
WO2011056021A3 (ko) 벤조헤테로사이클 유도체의 암 예방 및 치료 또는 암 전이 억제를 위한 용도
BRPI0607409A2 (pt) preparação de retardo em forma de comprimidos contra vertigem
WO2007022344A3 (en) Methods and compositions for the preventioin and treatment of kidney disease
MX2009010167A (es) Composicion farmaceutica solida que comprende un derivado de bencimidazol-7-carboxilato y un agente para el control del ph.
MX2010005012A (es) Composiciones para el tratamieno y prevencion de inflamacion de los parpados que comprenden un ingrediente osmoticamente activo y un vasocosntrictor.
IL191758A0 (en) Composition with sustained release of the active ingredient, process for the preparation thereof and use thereof
EP2015740A4 (en) NEW LOW-DOSED PHARMACEUTICAL COMPOSITIONS WITH NIMESULID, PREPARATION AND USE
BRPI0607412A2 (pt) preparação de ação retardada em forma de péletes contra vertigem
EP1940474A4 (en) ALBUMIN-BASED COLLOIDAL COMPOSITION HAVING AT LEAST ONE PROTECTED THIOL ZONE, METHODS OF PREPARATION AND METHODS OF USE
GB0502787D0 (en) Pharmaceuticlly active compounds, their manufacture, compositions containing them and their use
EP1952818A4 (en) OSTEOCLASTICIZATION PREPARATION, ORAL AGGREGATION AND PROPHYLACTIC OR THERAPEUTIC AGENT AGAINST BONE DISEASES WITH LACTOFERRIN-CONTAINING LIPOSOME
MX2009005578A (es) Derivados de aminoquinazolinas con propiedades reductoras de plaquetas de la sangre.
EP2801358A3 (en) The use of nicotine for diminishing pain in renal region in humans

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 9A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2307 DE 24/03/2015.